tiprankstipranks
Trending News
More News >
Vertex Pharmaceuticals Inc. (DE:VX1)
:VX1
Germany Market

Vertex Pharmaceuticals (VX1) Income Statement

Compare
23 Followers

Vertex Pharmaceuticals Income Statement

Last quarter (Q3 2025), Vertex Pharmaceuticals's total revenue was $3.08B, an increase of 10.99% from the same quarter last year. In Q3, Vertex Pharmaceuticals's net income was $1.08B. See Vertex Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 11.02B$ 9.87B$ 8.93B$ 7.57B$ 6.21B
Gross Profit
$ 9.49B$ 8.61B$ 7.85B$ 6.67B$ 5.47B
Operating Expenses
$ 9.72B$ 4.78B$ 3.54B$ 3.89B$ 2.61B
Depreciation and Amortization
$ 205.80M$ 181.30M$ 148.30M$ 125.60M$ 109.52M
EBITDA
$ 486.30M$ 4.61B$ 4.44B$ 2.92B$ 3.28B
Operating Income
$ -232.90M$ 3.83B$ 4.31B$ 2.78B$ 2.86B
Other Income/Expenses
$ 481.40M$ 547.80M$ -75.00M$ -51.70M$ 260.60M
Pretax Income
$ 248.50M$ 4.38B$ 4.23B$ 2.73B$ 3.12B
Net Income
$ -535.60M$ 3.62B$ 3.32B$ 2.34B$ 2.71B
Per Share Metrics
Basic EPS
$ -2.08$ 14.05$ 12.97$ 9.09$ 10.44
Diluted EPS
$ -2.08$ 13.89$ 12.82$ 9.01$ 10.29
Weighted Average Shares Outstanding
257.50M 257.70M 256.10M 257.70M 259.84M
Weighted Average Shares Outstanding (Diluted)
257.90M 260.50M 259.10M 259.90M 263.40M
Currency in USD

Vertex Pharmaceuticals Earnings and Revenue History